Crossject Société Anonyme (FRA:74C)

Market Cap	105.06M +155.8%
Revenue (ttm)	2.57M -37.6%
Net Income	-10.37M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	3.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	579
Open	1.860
Previous Close	1.878
Day's Range	1.860 - 1.860
52-Week Range	0.849 - 2.590
Beta	n/a
RSI	47.71
Earnings Date	Jun 24, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2001
• Employees: 103
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 74C

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.64% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.98% less than in 2024.